Compile Data Set for Download or QSAR
Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 489
TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272544((R)-6-(1-(4-fluorophenyl)ethyl)-3-(2-methylpyridin...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272560((R)-3-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-6-...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272790(US10065967, Example 41 | US9745307, Example 41 | U...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272541(US10065967, Example 7 | US9745307, Example 7 | US1...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272540(US10065967, Example 6 | US9745307, Example 6 | US1...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272538(3-(1-methyl-1H-pyrazol-4-yl)-1,8-dihydro-7H-pyrazo...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272554(US9745307, Example 20 | BDBM318128 | US10301317, E...)
Affinity DataIC50: 0.300nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272548(US10065967, Example 14 | US9624228, Example 372 | ...)
Affinity DataIC50: 0.5nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272547(3-(2-methylpyridin-4-yl)-5,6-dihydro-1H-pyrazolo[4...)
Affinity DataIC50: 0.600nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272563(US10065967, Example 28 | US9745307, Example 28 | U...)
Affinity DataIC50: 0.600nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272555(US10065967, Example 21 | US9745307, Example 21 | U...)
Affinity DataIC50: 0.600nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272551(US10065967, Example 17 | US10759805, Ex 17)
Affinity DataIC50: 0.700nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272552(US10065967, Example 18 | US9745307, Example 18 | U...)
Affinity DataIC50: 0.800nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272549((R)-3-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-6-...)
Affinity DataIC50: 1.70nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272553(US10065967, Example 19 | US9745307, Example 19 | U...)
Affinity DataIC50: 2.30nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272570(US10065967, Example 34)
Affinity DataIC50: 2.30nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272542(8-hydroxy-3-(2-methylpyridin-4-yl)-5,6-dihydro-1H-...)
Affinity DataIC50: 3.60nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272557(US10065967, Example 23 | US9745307, Example 23 | U...)
Affinity DataIC50: 3.70nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272550(US10065967, Example 16 | US9745307, Example 16 | U...)
Affinity DataIC50: 4.80nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272569((R)-methyl (7-oxo-6-(1-phenylethyl)-5,6,7,8-tetrah...)
Affinity DataIC50: 5.20nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272576(US10065967, Example 36 | US9745307, Example 36 | U...)
Affinity DataIC50: 6.40nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272791((R)-3-morpholino-6-(1-phenylethyl)-5,6-dihydro-1H-...)
Affinity DataIC50: 9nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272561(US10065967, Example 27 | US9745307, Example 27 | U...)
Affinity DataIC50: 10nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272788(US10065967, Example 39 | US9745307, Example 39 | U...)
Affinity DataIC50: 10nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272558(3-morpholino-1-pyrazolo[4,3-g]quinolin-7(8H)-one |...)
Affinity DataIC50: 12nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272786(US10065967, Example 37 | US9745307, Example 37 | U...)
Affinity DataIC50: 20nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272787(6-((R)-1-phenylethyl)-3-((tetrahydrofuran-3-yl)oxy...)
Affinity DataIC50: 21nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272568((R)-3-amino-6-(1-phenylethyl)-5,6-dihydro-1H-pyraz...)
Affinity DataIC50: 21nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272565((R)-3-(ethylamino)-6-(1-phenylethyl)-5,6-dihydro-1...)
Affinity DataIC50: 22nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272789((R)-3-cyclopropyl-6-(1-phenylethyl)-5,6-dihydro-1H...)
Affinity DataIC50: 24nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272556(US10065967, Example 22 | US9745307, Example 22 | U...)
Affinity DataIC50: 24nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272566(US10065967, Example 30 | US10759805, Ex 30)
Affinity DataIC50: 25nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272559(US10065967, Example 25 | US9745307, Example 25 | U...)
Affinity DataIC50: 42nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272792(US10065967, Example 43 | US9745307, Example 43 | U...)
Affinity DataIC50: 48nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272567(US10065967, Example 31 | US10759805, Ex 31)
Affinity DataIC50: 55nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272546((R)-7-(1-(4-fluorophenyl)ethyl)-3-(2-methyl pyridi...)
Affinity DataIC50: 72nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272575(US10065967, Example 35 | US9745307, Example 35 | U...)
Affinity DataIC50: 114nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272795(6-benzyl-3-(2-methylpyridin-4-yl)-1,8-dihydro-7H-p...)
Affinity DataIC50: 200nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272794(6-bromo-3-(2-methylpyridin-4-yl)-1,8-dihydro-7H-py...)
Affinity DataIC50: 200nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272539(US10065967, Example 5 | US9745307, Example 5 | US1...)
Affinity DataIC50: 228nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272543(3-(2-methylpyridin-4-yl)-5,6,7,9-tetrahydroazepino...)
Affinity DataIC50: 252nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272793(3-(2-methylpyridin-4-yl)-1,8-dihydro-7H-pyrazolo[4...)
Affinity DataIC50: 400nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM272545(7-(4-fluorobenzyl)-9-hydroxy-3-(2-methylpyridin-4-...)
Affinity DataIC50: 459nMAssay Description:Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was dete...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent